Combination of Moderna's mRNA cancer vaccine and antibody drug Keytruda cuts the risk of malignant melanoma recurrence and death by half
Combining an experimental mRNA cancer vaccine developed by American biotechnology company Moderna with German drug manufacturer Merck's antibody drug
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years
https://investors.modernatx.com/news/news-details/2023/Moderna-And-Merck-Announce-mRNA-4157-V940-In-Combination-with-KeytrudaR-Pembrolizumab-Demonstrated-Continued-Improvement-in- Recurrence-Free-Survival-and-Distant-Metastasis-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma-Following-Comple/default.aspx
Moderna's mRNA cancer vaccine works even better than thought
In July 2023, Moderna and Merck announced that Moderna's vaccine ``mRNA-4157 (V940)'' will be used as an adjuvant treatment for patients with stage IIB to IV malignant melanoma (a type of skin cancer) to the existing antibody drug ``Keytruda''. We have started testing for use in combination with ``.
Results showed that patients with stage III/IV disease, who are at a high risk of recurrence after complete resection, after a median of 3 years of treatment, had a 49% risk of melanoma recurrence or death compared with Keytruda monotherapy. The study revealed that the risk of distant metastasis or death was reduced by 62%.
To treat melanoma, a serious form of skin cancer, doctors usually begin by surgically removing as much of the cancer as possible. Other treatments such as chemotherapy and radiotherapy are then performed to kill the missed cancer cells, but depending on the type, there is a high risk of recurrence, especially those that are thick or that have metastasized before treatment. It may not be possible to remove it completely.
The vaccine created by Moderna instructs the body to make 'neoantigens,' proteins found only on cancer cells, which primes the immune system to quickly identify and attack new cancer cells that contain those proteins. This is to prevent recurrence.
'We are excited to have shown such robust clinical benefit in high-risk melanoma patients,' said Dr. Marjorie Green, Moderna's head of global clinical development, in a statement. It was the first demonstration of efficacy for a cancer drug and the first combination therapy to show a significant benefit compared to Keytruda alone.These data can be used to help people affected by the disease, We look forward to sharing it with the broader scientific community.'
Moderna's CEO said the vaccine could be released with accelerated approval in some regions by 2025.
Related Posts:
in Science, Posted by log1p_kr